BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

714 related articles for article (PubMed ID: 31300041)

  • 1. Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis.
    Rué L; Oeckl P; Timmers M; Lenaerts A; van der Vos J; Smolders S; Poppe L; de Boer A; Van Den Bosch L; Van Damme P; Weishaupt JH; Ludolph AC; Otto M; Robberecht W; Lemmens R
    Acta Neuropathol Commun; 2019 Jul; 7(1):114. PubMed ID: 31300041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing EphA4 before disease onset does not affect survival in a mouse model of Amyotrophic Lateral Sclerosis.
    Rué L; Timmers M; Lenaerts A; Smolders S; Poppe L; de Boer A; Van Den Bosch L; Van Damme P; Robberecht W; Lemmens R
    Sci Rep; 2019 Oct; 9(1):14112. PubMed ID: 31575928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense-mediated reduction of EphA4 in the adult CNS does not improve the function of mice with amyotrophic lateral sclerosis.
    Ling KK; Jackson M; Alkam D; Liu D; Allaire N; Sun C; Kiaei M; McCampbell A; Rigo F
    Neurobiol Dis; 2018 Jun; 114():174-183. PubMed ID: 29518482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inducible EphA4 knockout causes motor deficits in young mice and is not protective in the SOD1
    Dominguez SL; Earr T; Dourado M; Ngu H; Meilandt WJ; Hanson JE
    Sci Rep; 2020 Sep; 10(1):15713. PubMed ID: 32973290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans.
    Van Hoecke A; Schoonaert L; Lemmens R; Timmers M; Staats KA; Laird AS; Peeters E; Philips T; Goris A; Dubois B; Andersen PM; Al-Chalabi A; Thijs V; Turnley AM; van Vught PW; Veldink JH; Hardiman O; Van Den Bosch L; Gonzalez-Perez P; Van Damme P; Brown RH; van den Berg LH; Robberecht W
    Nat Med; 2012 Sep; 18(9):1418-22. PubMed ID: 22922411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex.
    Thomsen GM; Gowing G; Latter J; Chen M; Vit JP; Staggenborg K; Avalos P; Alkaslasi M; Ferraiuolo L; Likhite S; Kaspar BK; Svendsen CN
    J Neurosci; 2014 Nov; 34(47):15587-600. PubMed ID: 25411487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycogen accumulation modulates life span in a mouse model of amyotrophic lateral sclerosis.
    Brewer MK; Torres P; Ayala V; Portero-Otin M; Pamplona R; Andrés-Benito P; Ferrer I; Gentry MS; Guinovart JJ; Duran J
    J Neurochem; 2024 May; 168(5):744-759. PubMed ID: 37401737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Overexpression of TDP-43 Protein in the Neuron and Oligodendrocyte Cells Causes the Progressive Motor Neuron Degeneration in the SOD1 G93A Transgenic Mouse Model of Amyotrophic Lateral Sclerosis.
    Lu Y; Tang C; Zhu L; Li J; Liang H; Zhang J; Xu R
    Int J Biol Sci; 2016; 12(9):1140-9. PubMed ID: 27570488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll-Like Receptor-4 Inhibitor TAK-242 Attenuates Motor Dysfunction and Spinal Cord Pathology in an Amyotrophic Lateral Sclerosis Mouse Model.
    Fellner A; Barhum Y; Angel A; Perets N; Steiner I; Offen D; Lev N
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28763002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased signalling of EphA4 improves functional performance and motor neuron survival in the SOD1
    Zhao J; Cooper LT; Boyd AW; Bartlett PF
    Sci Rep; 2018 Jul; 8(1):11393. PubMed ID: 30061574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
    Milanese M; Giribaldi F; Melone M; Bonifacino T; Musante I; Carminati E; Rossi PI; Vergani L; Voci A; Conti F; Puliti A; Bonanno G
    Neurobiol Dis; 2014 Apr; 64():48-59. PubMed ID: 24361555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vivo effects of knocking-down metabotropic glutamate receptor 5 in the SOD1
    Bonifacino T; Cattaneo L; Gallia E; Puliti A; Melone M; Provenzano F; Bossi S; Musante I; Usai C; Conti F; Bonanno G; Milanese M
    Neuropharmacology; 2017 Sep; 123():433-445. PubMed ID: 28645622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of the astrocytic TNFR1-GDNF axis accelerates motor neuron degeneration and disease progression in amyotrophic lateral sclerosis.
    Brambilla L; Guidotti G; Martorana F; Iyer AM; Aronica E; Valori CF; Rossi D
    Hum Mol Genet; 2016 Jul; 25(14):3080-3095. PubMed ID: 27288458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epothilone D accelerates disease progression in the SOD1
    Clark JA; Blizzard CA; Breslin MC; Yeaman EJ; Lee KM; Chuckowree JA; Dickson TC
    Neuropathol Appl Neurobiol; 2018 Oct; 44(6):590-605. PubMed ID: 29380402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of altered ephrin-A5 and EphA4/EphA7 expression on tumor growth in a medulloblastoma mouse model.
    Bhatia S; Hirsch K; Baig NA; Rodriguez O; Timofeeva O; Kavanagh K; Lee YC; Wang XJ; Albanese C; Karam SD
    J Hematol Oncol; 2015 Sep; 8():105. PubMed ID: 26345456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vivo genetic ablation of metabotropic glutamate receptor type 5 slows down disease progression in the SOD1
    Bonifacino T; Provenzano F; Gallia E; Ravera S; Torazza C; Bossi S; Ferrando S; Puliti A; Van Den Bosch L; Bonanno G; Milanese M
    Neurobiol Dis; 2019 Sep; 129():79-92. PubMed ID: 31102766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axonal degeneration, distal collateral branching and neuromuscular junction architecture alterations occur prior to symptom onset in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
    Clark JA; Southam KA; Blizzard CA; King AE; Dickson TC
    J Chem Neuroanat; 2016 Oct; 76(Pt A):35-47. PubMed ID: 27038603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulation of Steroid Hormone Receptors in Motor Neurons and Glia Associates with Disease Progression in ALS Mice.
    McLeod VM; Chiam MDF; Lau CL; Rupasinghe TW; Boon WC; Turner BJ
    Endocrinology; 2020 Sep; 161(9):. PubMed ID: 32621747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of RAGE inhibition on the progression of the disease in hSOD1
    Liu L; Killoy KM; Vargas MR; Yamamoto Y; Pehar M
    Pharmacol Res Perspect; 2020 Aug; 8(4):e00636. PubMed ID: 32776498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caspase 6 has a protective role in SOD1(G93A) transgenic mice.
    Hogg MC; Mitchem MR; König HG; Prehn JH
    Biochim Biophys Acta; 2016 Jun; 1862(6):1063-73. PubMed ID: 26976329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.